Introduction
============

Pancreatic ductal adenocarcinoma (PDAC), characterized with insidious onset and early metastasis, is one of the most life-threating diseases with an extremely low 5-year survival rate, only 6% in USA [@B1]. Even after resection with curative intent, most patients suffer from recurrence [@B2].

The prognosis of PDAC is evaluated by American Joint Committee on Cancer (AJCC) staging system. Adding a N2 classification for nodal status (N0: no pN; N1: 1-3 pNs; N2: ≥4 pNs) and only considering tumor size regardless of extrapancreatic extension (T1: ≤2cm, T2: \>2cm and ≤4cm, T3: \>4cm), the discriminatory power of 8^th^ AJCC schemes is still comparable with 7^th^ AJCC schemes [@B3], [@B4].

Significant differences in lymphatic backflow and innervations between the head and body/tail of the pancreas have prognostic effect on PDAC [@B5], which is not reflected on the 8^th^ AJCC staging scheme.

Nodal status is a potent prognostic factor [@B6]-[@B9]. Ignoring total number of examined lymph nodes (eNs), pNs perform well when the number of eNs is more than 20 [@B10], [@B11]. Besides, 15 eNs are needed to ensure node-negative status of PDAC [@B12]. However, the number of eNs is insufficient in many cases, which results in false negative nodal status [@B13], and the number of eNs needed for good prognosis is uncertain.

The lymph nodes ratio (LNR, pNs divided by eNs) is selected as a parameter for nodal status and occasionally proved to be superior to pNs, especially for node-positive PDAC [@B14]-[@B16].

Our aim is to identify the number of eNs needed for good prognosis, to modify the staging schemes for resectable PDAC by recursive partitioning analysis (RPA), and to explore the interactions among parameters included.

Methods
=======

Patients
--------

The Surveillance, Epidemiology, and End Results (SEER) database was used. We identified patients with PDAC (ICD-O-3 codes: 8140, 8150, 8210, 8211, 8251, 8260, 8261, 8263, 8480, 8481, 8490, 8500, and 8503) from 2004 to 2014. Exclusion criteria included: history of prior malignancy, T4 stage in 8^th^ AJCC scheme, distant metastasis and missing information regarding overall survival (OS), tumor sizes, number of pNs and eNs. Finally, 8480 patients, which were further divided into training cohort (n=5936) and internal validation cohort (n=2544) randomly, were included.

The external validation cohort consisted of patients from Sun Yat-sen University Cancer Center (SYSUCC, from 2001 to 2016). All the patients (n=92) were pathologically diagnosed with PDAC. Patients with missing data on tumor sizes, nodal status or survival were excluded.

Statistical Analysis
--------------------

OS was regarded as primary outcome. Kaplan-Meier method and log-rank tests were applied to assess prognostic effect. Cox proportional hazards regression was used for univariate analysis and multivariable analysis. To identify risk factors of positive nodal status, Logistic regression was applied [@B17].

To modify the staging scheme, RPA, which was able to classify patients into groups of maximum separation [@B18], [@B19], was applied. R package named "rpart" was used to develop RPA model, classifying patients into different subgroups with different prognosis using selected parameters automatically, and "rpart.plot" package was applied to visualized result of RPA. For subgroups with similar median survival time, we merged them into bigger groups manually to generate our refined staging system.

Concordance index (c-index), ranging from 0.5 to 1, was used for quantifying discriminatory capacity. The higher c-index, the better discriminatory capacity [@B20]. When assessing prognostic homogeneity, we compared OS within each stage of our model by 8^th^ AJCC stages and likelihood ratio χ^2^ test was also applied.

P\<0.05 was regarded as statistical significance. IBM SPSS Statistics for Windows v.19.0 and R v.3.4.1 were used for statistical analysis.

Results
=======

Characteristics of Patients from SEER Database
----------------------------------------------

Characteristics of 8480 patients from SEER database were shown in Table [S1](#SM0){ref-type="supplementary-material"}. Most of tumors were located in head of pancreas (84.5%), with the greatest dimension between 2cm and 4cm (59.6%), while median OS was 20 months.

For node-positive patients, more eNs were found (p\<0.001), locations of tumor tended to be head of pancreas (p\<0.001) and sizes of tumor were larger (p\<0.001) (Table [S2](#SM0){ref-type="supplementary-material"}).

Tumors in head of pancreas tended to have more eNs (p\<0.001), more pNs (p\<0.001) and smaller tumor sizes (p\<0.001). Besides, LNR tended to be higher for PDAC in head (LNR: head of pancreas: 0.175, 95% confidence interval (CI) 0.171-0.180; LNR: body and tail of pancreas: 0.124, 95% CI 0.113-0.134, p\<0.001), which implies that tumors in head are prone to lymph node metastasis (Table [S3](#SM0){ref-type="supplementary-material"}).

Characteristics of Patients from SYSUCC
---------------------------------------

Characteristics of 92 patients from SYSUCC were shown in Table [1](#T1){ref-type="table"}. Median age at diagnosis was 59 years old. Nearly 60% patients were male. Most of tumors were located in head of pancreas (83.7%). The median OS was 23 months.

Risk Factors for Positive Nodal Status
--------------------------------------

For patients from SEER database, we identified tumor site (HR=2.132, 95% CI 1.876-2.423, p\<0.001), tumor size (HR=1.016, 95% CI 1.013-1.020, p\<0.001) and the number of eNs (HR=1.050, 95% CI 1.044-1.056, p\<0.001) as risk factors for positive nodal status, while race (p=0.057), sex (p=0.190), age of diagnosis (p=0.381) and histologic type of PDAC (p=0.174) were not.

Prognostic Factors
------------------

In training cohort, for node-positive patients, univariate analysis identified age of diagnosis (p\<0.001), year of diagnosis (p\<0.001), grade of PDAC (p=0.002), tumor size (p\<0.001), the number of pNs (p\<0.001) and eNs (p\<0.001) and LNR (p\<0.001) as risk factors, while sex (p=0.119), histologic type (p=0.319), race (p=0.819), tumor site (p=0.355), marital status (p=0.197) were not. Multivariable analysis showed that age of diagnosis (HR=1.012, 95% CI 1.008-1.015, p\<0.001), year of diagnosis (HR=0.982, 95% CI 0.969-0.996, p=0.011), grade (HR=1.036, 95%CI 1.014-1.059, p=0.001), tumor size (HR=1.002, 95%CI 1.001-1.003, p=0.001), pNs (HR=1.025, 95% CI 1.006-1.044, p=0.011), eNs (HR=0.991, 95%CI 0.985-0.997, p=0.005) and LNR (HR=1.912, 95% CI 1.912-2.563, p\<0.001) were independent risk factors for node-positive PDAC.

For nodes-negative patients, similarly, age of diagnosis (HR=1.019, 95%CI 1.013-1.024, p\<0.001), year of diagnosis (HR=0.950, 95%CI 0.929-0.971, p\<0.001), tumor site (HR=1.119, 95%CI 1.027-1.378, p=0.021), eNs (HR=0.987, 95%CI 0.980-0.994, p\<0.001) and tumor size (HR=1.009, 95%CI 1.007-1.011, p\<0.001) were independent risk factors for node-negative PDAC.

Refined Model in Training Cohort
--------------------------------

For node-positive patients, risk factors of positive nodal status (T stage of 8^th^ AJCC, eNs and site of tumor) and parameters for nodal status (LNR and pNs) were put into RPA. For node-negative patients, risk factors of positive nodal status (T stage of 8^th^ AJCC, eNs, site of tumor) were used. LNR, T stage of 8^th^ AJCC and eNs were selected as parameters of our staging system by RPA for node-positive patients, while T stage, eNs and tumor locations for node-negative patients. After RPA was done for node-positive and node-negative patients respectively, we combine them together and merge subgroups with similar median survival time into the same group, as it was in Figure [S1](#SM0){ref-type="supplementary-material"}. For convenience, we summarized results of RPA in Table [2](#T2){ref-type="table"}, which was easier to understand and use. Remarkably, for node-positive patients, LNR was the first parameter to be taken into consideration by RPA, which implied that LNR was of the great importance in prognosis of patients with positive nodal status, corresponding with multivariable analysis above.

LNR, which was selected by RPA, was divided as follow: R0 (LNR=0), R1 (0\<LNR\<0.24), R2 (0.24≤LNR\<0.45) and R3 (LNR≥0.45) (Figure [1](#F1){ref-type="fig"}a). Diagnostic effects of T stage were shown in Figure [1](#F1){ref-type="fig"}b. Our staging scheme classified patients into 5 groups: RPA-I (R0T1 in body&tail of pancreas and R0T1 in head of pancreas with eNs \>2.5), RPA-II (R0T2 with eNs \>5.5, R0T2 in the body&tail of pancreas with eNs\<5.5 and R1T1), RPA-III (R0T1 in head of pancreas with eNs \<2.5, R0T2 in the head of pancreas with eNs \<5.5, R0T3 with eNs \>5.5, R0T3 in the body&tail of pancreas with eNs\<5.5, R1T2-T3 with eNs \>9.5 and R2T1), RPA4-Ⅳ (R0T3 in the head of pancreas with eNs \<5.5, R1T2-T3 with eNs \<9.5 and R2T2-T3) and RPA-V (R3T1-T3) (Table [2](#T2){ref-type="table"}, Figure [S1](#SM0){ref-type="supplementary-material"}). Notably, for node-negative patients, 6 eNs or more implied good prognosis.

488, 1303, 2376, 1174 and 595 patients were included in RPA-I, RPA-II, RPA-III, RPA-IV and RPA-V groups with a median survival of 47, 26, 20, 15 and 12 months (p\<0.001), respectively (Figure [1](#F1){ref-type="fig"}c). Adjusted with sex, age of diagnosis, histologic type, race, year of diagnosis, marital status and grade, our model showed that the advanced stage correlated with elevated risk of poor prognosis (RPA-II vs RPA-I: HR 1.644, 95% CI 1.412-1.914, p\<0.001; RPA-III vs RPA-I: HR 2.261, 95% CI 1.959-2.610, p\<0.001; RPA-IV vs RPA-I: HR 3.263, 95% CI 2.809-3.790, p\<0.001; RPA-V vs RPA-I: HR 4.026, 95% CI: 3.427-4.731, p\<0.001).

Evaluation of Performance
-------------------------

In training set, compared to the 8^th^ AJCC staging scheme (Figure [1](#F1){ref-type="fig"}d) (c-index: 0.577, 95% CI 0.567- 0.587), our staging system displayed a better performance of discriminatory ability (c-index: 0.606, 95% CI 0.596-0.616, p\<0.001). For prognostic homogeneity, our staging scheme (likelihood ratio χ^2^ test= 547.2) was also better than 8^th^ AJCC scheme (likelihood ratio χ^2^ test= 345.4) (Table [3](#T3){ref-type="table"}). Our model can classify patients of 8^th^ AJCC stages into subgroups with different OS. Stratified by 8^th^ AJCC stages, OS was homogeneous for patients in our scheme (Table [4](#T4){ref-type="table"}).

Characteristics were comparable between training and internal validation cohort (Table [S4](#SM0){ref-type="supplementary-material"}). For internal validation cohort, c-index of our staging system (c-index: 0.597, 95% CI: 0.581-0.613) was higher than 8^th^ AJCC (c-index: 0.583, 95% CI 0.567-0.599, p=0.004) (Figure [1](#F1){ref-type="fig"}e, 1f). Stage-IB, stage-IIB and stage-III in 8^th^ AJCC staging scheme (likelihood ratio χ^2^ test= 157.2) can be classified by our staging system (likelihood ratio χ^2^ test=208.1) into subgroups with distinct OS, while OS was homogeneous in each stage of our system stratified by 8^th^ AJCC scheme (Table [3](#T3){ref-type="table"}, Table [S5](#SM0){ref-type="supplementary-material"}).

For patients from SYSUCC, our staging model also displayed a better performance of discriminatory ability (c-index of our refined model was 0.565, while c-index of 8^th^ AJCC staging scheme was 0.558) and prognostic homogeneity (likelihood ratio χ^2^ test of our refined model was 4.24, while likelihood ratio χ^2^ test of 8^th^ AJCC staging system was 2.64).

Tumor Size and Nodal Status
---------------------------

Higher proportion of positive nodal status was found in high T stage (p\<0.001) (Table [S6](#SM0){ref-type="supplementary-material"}). Patients of T1 tended to have less pNs than T2-3 patients (p\<0.001, Figure [2](#F2){ref-type="fig"}a). A cumulative frequency diagram of PDAC with diameter less than 4cm showed that when diameters were less than 10mm, few events of metastasis were found (Figure [2](#F2){ref-type="fig"}b).

Effects of Tumor Site on Prognosis
----------------------------------

For patients of R0T1 in our scheme, OS was significantly different between different sites of tumor (p=0.004, Figure [2](#F2){ref-type="fig"}c). Besides, for patients of T1 or R0 with eNs\<5.5, OS was significantly different between different sites (p\<0.001, p=0.040, respectively. Figure [2](#F2){ref-type="fig"}d, 2h). However, for patients of T3, R0 and R3, OS of different sites were homogeneous (p=0.283, p=0.460 and p=0.651, respectively (Figure [2](#F2){ref-type="fig"}e, 2f and 2g).

Comparisons: R0 with eNs\<5.5 Patients and 0\<LNR\<0.078 Patients
-----------------------------------------------------------------

Patients of R1 in our model were further divided using LNR by RPA. It was revealed that prognosis of patients with 0\<LNR\<0.078 was better than others (p\<0.001, Figure [1](#F1){ref-type="fig"}g). There was no significant difference in OS between patients of R0 with eNs\<5.5 and patients with 0\<LNR\<0.078 (p=0.341, Figure [1](#F1){ref-type="fig"}h), which supported that if eNs were less than 6, negative nodal status may be false-negative (Table [S7](#SM0){ref-type="supplementary-material"}).

Discussion
==========

Our staging model shows better performance than 8^th^ AJCC scheme for resectable PDAC in internal validation cohort from SEER database and external validation cohort from SYSUCC. Site of tumor and eNs were introduced into our scheme, and the number of pNs is replaced by LNR.

Nodal status is a potent prognostic factor for resectable PDAC [@B6]. pNs were selected as parameter for nodal status in 8^th^ AJCC staging scheme. However, there are different clinical meanings for finding a positive node with different eNs. LNR, considering both pNs and eNs, was said to have preeminent prognostic effects [@B14]-[@B16]. Multivariable analysis confirmed that for node-positive patients, prognostic effect of LNR (HR=1.912) was more powerful than pNs (HR=1.025) in this study. After putting both pNs and LNR together into RPA, LNR is chosen in our model, implying that LNR may be a better parameter for node-positive patients.

Previous study showed that 15 eNs were needed for accuracy of staging, decreasing the false negative rate of nodal status [@B12]. A study for gastric cancer incorporated node-negative patients with insufficient eNs into node-positive group, which implies that insufficient eNs may result in poor prognosis and false-negative nodal status [@B13]. We focus on the number of eNs needed for good prognosis, finding that 6 eNs are needed for good prognosis of node-negative patients, suggesting that at least 6 eNs are expected after resection.

Characteristics of PDACs in different sites of pancreas are different [@B21]. Our study implied that for patients with small tumor and node-negative patients with insufficient eNs, tumors in the head of pancreas led to poor prognosis, possibly because of their tendency to lymph nodes metastasis. However, the underlying molecule mechanisms are needed to be explored.

When diameters of PDAC are less than 1cm, few positive nodes are found. Local tumor growth is a vital step for metastasis [@B22]. As tumor grows, proliferating tumor cells, insufficient blood supply and poor lymph drainage result in activation of VEGF-C/Flt-4 axis and hypoxia signaling pathway, promoting lymphangiogenesis and making cancer cell more aggressive, which accelerates metastasis of cancer [@B23]-[@B25]. That corresponds with our finding.

RPA, dichotomizing populations into subsets step by step repeatedly [@B26] by suitable parameters and cut-off value to maximize the change [@B27], [@B28], is widely used in tumor staging [@B19], [@B29]-[@B31], while nomograms combine prognostic factors to predict clinical outcome [@B32], [@B33]. However, cumbersome calculation limits nomograms\' uses in clinical practice [@B34]. Our RPA model has the following advantages. Firstly, without cumbersome calculation of scores which limits nomograms\' uses, it is easy to use our model to evaluate prognosis of PDAC patients in clinical practices, which is helpful for decision-making of clinicians. Secondly, RPA, a kind of decision tree model [@B35], can handle lots of variables at a time and show importance ranking of variables [@B36]. The more important a variable is, the closer it is to the "root" of the decision tree. For example, in our model, LNR is the closest to the "root" of tree in node-positive patients (Figure [S1](#SM0){ref-type="supplementary-material"}), which means that compared to other parameters included, LNR is the most important prognostic variable, corresponding with our multivariable analysis. Thirdly, our RPA model can help to understand interactions among included parameters. For example, for R0T1 patients in our model, location of tumor is an important prognostic factor. However, for patients with high LNR, tumor site is not taken into consideration, which implies that tumor site may be more important for PDAC of early stage. Last but not the least, as both continuous variables and nominal variables can be handled by RPA. The best cut-off value for division of patients into different prognosis can be found for continuous variables. In our study, 6 eNs was found by RPA as cut-off value for eNs to improve prognosis of node-negative patients.

When assessing prognostic homogeneity in internal validation set, stage-IA and IIA of 8^th^ AJCC can\'t be stratified by our staging model (Table [S5](#SM0){ref-type="supplementary-material"}), as a result of insufficient number of patients. Prognostic effects of eNs are based on the hypothesis that insufficient eNs may result in high rate of false negative of nodal status, meaning that eNs show predictive power when samples size is large enough.

There several limitations. First, coding errors are reported to remain in SEER database [@B37]. Besides, additional therapies, such as adjuvant chemotherapy, are not considered because of information unavailable. Thirdly, the number of patients in SYSUCC cohort may be not enough compared to patients from SEER database.

In short, we develop a refined staging scheme incorporating tumor size, tumor site, eNs and LNR, illustrating their interactions.
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Supplementary figure and tables.
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Click here for additional data file.
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![(a) the number of positive lymph nodes (pNs) in patients of T1 stage and T2-3 stage; (b) A cumulative frequency diagram of tumor diameter and frequency of lymph nodes metastasis; Overall survival by tumor site for patients of (c)R0T1; (d) T1; (e) T3; (f) R0; (g) R3; (h) R0 with eNs \<5.5. (R0: LNR=0, R1: 0\<LNR\<0.24, R2: 0.24≤LNR\<0.45 and R3: LNR≥0.45; T1: ≤2cm, T2:\>2cm and ≤4cm, T3: \>4cm; LNR: positive lymph nodes ratio; eNs: examined lymph nodes).](jcav09p3507g002){#F2}

###### 

Characteristics of patients from Sun Yat-sen University Cancer Center.

  -----------------------------------------------------
  Variable                             Median(IQR)/N%
  ------------------------------------ ----------------
  **Age(years)**                       59(50-66)

  Sex                                  

  Male                                 56(60.9%)

  Female                               36(39.1%)

  **Tumor site**                       

  head                                 77(83.7%)

  body or tail                         15(16.3%)

  **Tumor differentiation**            

  well-moderate                        6(6.5%)

  Moderate                             36(39.1%)

  Moderate-poor\                       31(33.7%)
  poor                                 

  15(16.3%)                            

  not determined                       4(4.3%)

  **Tumor size**                       

  ≤2cm                                 9(9.8%)

  \>2cm and ≤4cm                       54(58.7%)

  \>4cm                                29(31.5%)

  **number of positive lymph node**    0(0-1)

  0 positive lymph node                50(54.3%)

  1-3 positive lymph nodes             34(40.0%)

  ≥4 positive lymph nodes              8(8.7%)

  **number of examined lymph nodes**   8.5(4-14)
  -----------------------------------------------------

Abbreviations: IQR = interquartile range

###### 

Refined staging scheme for resectable PDAC by recursive partitioning analysis. MS: median survival (R0: LNR=0, R1: 0\<LNR\<0.24, R2: 0.24≤LNR\<0.45 and R3: LNR≥0.45; T1: ≤2cm, T2:\>2cm and ≤4cm, T3: \>4cm; head: head of pancreas, body&tail: body and tail of pancreas; RPA: recursive partitioning analysis).

  R          T           eNs       site        stage
  ---------- ----------- --------- ----------- ---------
  R0         T1          Any       Body&Tail   RPA-I
  eNs\>2.5   Head        RPA-I                 
  eNs\<2.5   Head        RPA-III               
  T2         eNs\>5.5    Any       RPA-II      
  eNs\<5.5   Body&Tail   RPA-II                
  Head       RPA-III                           
  T3         eNs\>5.5    Any       RPA-III     
  eNs\<5.5   Body&Tail   RPA-III               
  Head       RPA-IV                            
  R1         T1          Any       Any         RPA-II
  T2, T3     eNs\>9.5    Any       RPA-III     
  eNs\<9.5   Any         RPA-IV                
  R2         T1          Any       Any         RPA-III
  T2, T3     Any         Any       RPA-IV      
  R3         Any         Any       Any         RPA-V

###### 

Comparison of the performance of our refined model and 8^th^ AJCC staging system

                                         c-index   likelihood ratio ×2 test           
  -------------------------------------- --------- -------------------------- ------- -------
  training cohort of SEER                0.577     0.606                      345.4   547.2
  internal validation cohort of SEER     0.583     0.597                      157.2   208.1
  external validation cohort of SYSUCC   0.558     0.565                      2.64    4.24

###### 

Prognostic homogeneity comparison between 8^th^ AJCC staging system and our staging system in training set

            8th AJCC-IA   8th AJCC-IB   8th AJCC-IIA   8th AJCC-IIB   8th AJCC-III                               
  --------- ------------- ------------- -------------- -------------- -------------- ---- ------ ---- ----- ---- ---------
  RPA-I     488           47                                                                                     
  RPA-II                                946            27                                 315    26   42    30   p=0.406
  RPA-III   35            16            184            20             356            20   1447   20   354   18   p=0.460
  RPA-IV                                                              49             13   554    14   571   16   p=0.600
  RPA-V                                                                                   136    10   459   13   p=0.119
  p-value   P\<0.001      p\<0.001      p=0.001        p\<0.001       p\<0.001                                   

Abbreviations: AJCC= American Joint Committee on Cancer; MS=median survival; RPA=recursive partitioning analysis.
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